REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact…
Biotechnology
US, Rockville [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about REGENXBIO Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | - | -1.880 | - | 4 | - | -82 | - | -3 | - | -3 | - | 3 |
| 2016 | -2.4900 | -2.343 | 7 | 5 | -22 | -102 | -22 | -3 | -23 | -3 | 11 | 4 |
| 2017 | -2.3800 | -2.747 | 4 | 8 | -62 | -120 | -64 | -6 | -65 | -6 | 23 | 6 |
| 2018 | -2.4500 | 2.870 | 10 | 207 | -73 | 120 | -73 | 134 | -75 | 104 | 27 | 51 |
| 2019 | 2.7300 | -2.394 | 218 | 53 | 99 | -67 | 92 | -62 | 88 | -139 | 36 | 48 |
| 2020 | -2.5800 | -2.853 | 35 | 159 | -94 | -124 | -90 | -108 | -148 | -110 | 51 | 120 |
| 2021 | -2.9800 | 3.892 | 154 | 492 | -111 | 170 | -96 | -334 | -119 | -342 | 63 | 372 |
| 2022 | 3.0100 | -6.189 | 470 | 120 | 127 | -155 | 169 | -135 | 159 | -151 | 79 | 50 |
| 2023 | -6.5000 | -5.516 | 112 | 118 | -280 | -263 | -244 | -140 | -262 | -156 | 85 | 52 |
| 2024 | -6.0200 | -4.720 | 90 | 86 | -263 | -205 | -239 | -56 | -268 | -58 | 88 | 65 |
| 2025 | - | -0.962 | - | 298 | - | -55 | - | -194 | - | -199 | - | 226 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |